Results 71 to 80 of about 86,566 (299)

Characterization of HIV-1 Integrase Reactions with Viral DNA [PDF]

, 2013
HIV-1 integrase (integrase) catalyzes the insertion of viral DNA into human chromosomes and is a focus for development of anti-integrase inhibitors to combat HIV infection. Integrase catalyzes two steps, a DNA-end cleavage reaction (3’-processing), and a
Kettlewell, Joanna
core   +1 more source

Rational Design of Optical Single‐Walled Carbon Nanotube‐Based Nanosensors with Biological Recognition Elements

Advanced Sensor Research, EarlyView.
This Review focuses on assessing and providing perspective on the field of rationally‐designed optical sensors constructed with single‐walled carbon nanotubes. The literature is reviewed and evaluated for SWCNT‐based sensors constructed with biomolecular recognition elements, including proteins, peptides, and oligonucleotides, as well as their methods ...
Amelia K. Ryan, Atara Israel, Maria Celina Stefoni, Catarina Ferraz, Ryan M. Williams   +4 more
wiley   +1 more source

LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV

EBioMedicine, 2016
Persistence of latent, replication-competent Human Immunodeficiency Virus type 1 (HIV-1) provirus is the main impediment towards a cure for HIV/AIDS (Acquired Immune Deficiency Syndrome). Therefore, different therapeutic strategies to eliminate the viral
Lenard S. Vranckx, Jonas Demeulemeester, Suha Saleh, Annegret Boll, Gerlinde Vansant, Rik Schrijvers, Caroline Weydert, Emilie Battivelli, Eric Verdin, Anna Cereseto, Frauke Christ, Rik Gijsbers, Zeger Debyser   +12 more
doaj   +1 more source

Comparative antiviral activity of integrase inhibitors in human monocyte-derived macrophages and lymphocytes [PDF]

, 2011
The activity of raltegravir and 4 other integrase inhibitors (MK-2048, L870,810, IN2, and IN5) was investigated in primary human macrophages, PBMC and C8166-lymphocytic T cells, in order to determine their relative potency and efficacy in different ...
Aquaro, S, Ceccherini-Silberstein, F, Perno, C, Pollicita, M, Santo, F, Scopelliti, F, Surdo, M   +6 more
core   +1 more source

HIV Dynamics and Integrase Inhibitors

Antiviral Chemistry and Chemotherapy, 2009
The integrase inhibitor (INI) raltegravir has shown promising results in clinical trials to date, reducing second phase HIV RNA levels by 70% in comparison with standard regimens. These trial results have been limited by the 50 copies/ml detection limit of the HIV RNA assay and have not investigated the effect of an INI regimen on levels of latently ...
openaire   +2 more sources

HIV-1 Integrase Inhibitors

Drugs in R & D, 2007
From the discovery of HIV-1 integrase (IN) inhibitors using enzyme-based assays in 1992, it has taken 15 years to achieve success in human clinical trials. Currently available antiretroviral drugs set high clinical standards in efficacy and long-term safety for upcoming novel HIV/AIDS therapeutic agents.
Raveendra, Dayam, Laith Q, Al-Mawsawi, Nouri, Neamati   +2 more
openaire   +2 more sources

Physiologically based pharmacokinetic model combined with a clinical lactation study to determine doravirine concentrations in human breastmilk

British Journal of Clinical Pharmacology, EarlyView.
Aims To determine breastmilk concentrations of doravirine via PBPK modelling in combination with a clinical lactation study. As women living with HIV are not able to cease antiretroviral therapy during lactation, it is necessary to establish drug transfer into breastmilk to determine exposure of the infant to antiretroviral drugs and potential risk of ...
Lena van der Wekken‐Pas, David Burger, Rick Greupink, Angela Colbers   +3 more
wiley   +1 more source

RNA interference approaches for treatment of HIV-1 infection. [PDF]

, 2015
HIV/AIDS is a chronic and debilitating disease that cannot be cured with current antiretroviral drugs. While combinatorial antiretroviral therapy (cART) can potently suppress HIV-1 replication and delay the onset of AIDS, viral mutagenesis often leads to
Bobbin, Maggie L, Burnett, John C, Rossi, John J   +2 more
core   +1 more source

Pharmacokinetics of dolutegravir, tenofovir and lamivudine during venous–venous extracorporeal membrane oxygenation (VV‐ECMO): A case report

British Journal of Clinical Pharmacology, EarlyView.
While providing potentially life‐saving cardiorespiratory support for critically ill patients, extracorporeal membrane oxygenation (ECMO) may detrimentally affect pharmacokinetic (PK) performance and concurrent drug efficacy and safety. We describe a patient with Pneumocystis jirovecii pneumonia (PJP) in the context of acquired immunodeficiency ...
Tom C. Zwart, Emiel Leegwater, Thomas H. Ottens, Emile F. Schippers, Erik B. Wilms, David M. Burger, Cees van Nieuwkoop, Liesbeth B. E. Bosma   +7 more
wiley   +1 more source

Viral Dynamic Model of Antiretroviral Therapy Including the Integrase Inhibitor Raltegravir in Patients with HIV-1

Biomath, 2012
Antiviral combination therapies consisting of reverse transcriptase inhibitors, protease inhibitors and an integrase inhibitor, have been developed to suppress HIV below the limit of detection.
Dimitra Bon, Christoph Stephan, Oliver Keppler, Eva Herrmann   +3 more
doaj   +1 more source